Research

Autoantibody Biomarker Discovery

Systemic Lupus Erythematosus (SLE)

Study Design:

  • Identification of novel autoantibodies in SLE and stratification of subgroups of SLE individuals.

Results:

  • 4 SLE subgroups were categorised based on hierarchical clustering and principal component analysis (PCA) with known autoantigens such as TROVE2 (Ro60) and SSB (La) forming a single cluster and novel TGF-β signalling (SMAD2 and SMAD5) and TLR signalling (My88) autoantigens forming another cluster.


Drug Companion Diagnostics

Checkpoint Inhibitor Melanoma Trial

Study Design:

  • Metastatic melanoma, BRAF mutant patients, treated with experimental checkpoint inhibitor drugs.

Results:

  • Stratified patients into 3 cohorts (responsive, non-responsive, toxic).


Protein Interaction Assays

DNA-Protein Interaction Study

Study Design:

  • p53 microarray printed onto a neutravidin-derivatised dextran hydrogel surface probed with Cy3-labelled GADD45 duplex oligo

Results:

  • Quantitative parallel thermodynamic analysis revealed previously unknown functional effects of mutation on p53 protein-DNA interaction

  • Differential DNA binding activity of p53 mutant proteins

  • Quantitative analysis unravels mechanistic differences between ‘loss of function’ mutations 

FEATURED PRODUCTS

IMMUNOME
Protein Array

High-throughput
sero-profiling platform

CTA
Protein Array

Screening of
cancer-testis antigens

OncoREX p53
Cancer Array

Cancer drug
screening and discovery

Custom
Protein Array

Flexible format for
high-throughput screening

2008 – 2019 © Sengenics All rights reserved 

2008 – 2019 © Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

X